A Non-Randomized Phase Ib-II Protocol of Paclitaxel, Carboplatin and the Dual PI3K/mTOR Kinase Inhibitor, PF-05212384, for Patients With Advanced, or Metastatic Non-Small Cell Carcinoma of the Lung

Trial Profile

A Non-Randomized Phase Ib-II Protocol of Paclitaxel, Carboplatin and the Dual PI3K/mTOR Kinase Inhibitor, PF-05212384, for Patients With Advanced, or Metastatic Non-Small Cell Carcinoma of the Lung

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs Carboplatin (Primary) ; Gedatolisib (Primary) ; Paclitaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2017 Planned End Date changed from 30 Jul 2022 to 30 Aug 2022.
    • 01 Aug 2017 Planned primary completion date changed from 30 Jul 2020 to 30 Aug 2020.
    • 30 Jun 2017 Planned End Date changed from 30 Jun 2022 to 30 Jul 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top